Abstract:Plasmatic CLUSTERIN (CLU) is increased in Alzheimer's disease (AD) but neither in mild cognitive impairment nor in controls who subsequently convert to AD. Plasmatic CLU may be used as one of the proteins in a panel of proteins enabling measurement of the AD plasma signature. Early diagnosis of late‐onset Alzheimer's disease (AD) by peripheral biomarkers remains a challenge; many have been proposed, but none have been evaluated in a prospective manner. CLUSTERIN (CLU), a chaperone protein expressed in the brain and found in relatively high concentrations in plasma, is a promising candidate. CLU contributes to the elimination of β‐amyloid (Aβ), which is associated to neurofibrillary tangles and to the genetic risk for AD. We performed a longitudinal measurement of CLU in the brain and the plasma in 3xTgAD mice. Assessment of CLU was also conducted in 12‐month‐old TgF344‐AD rats. In humans, brain CLU was measured in non‐demented and in AD subjects. The plasma CLU was longitudinally measured in four cohorts defined as healthy controls that remained stable, healthy controls that presented a cognitive decline between the two measures, mild cognitive impairment (MCI) that presented a cognitive decline between the two measures and AD. A validation cohort composed of 19 MCI was used and plasma CLU was measured before and after conversion in AD. Increases in CLU were measured in the hippocampus of 3xTgAD and TgF344‐AD animals in the absence of plasmatic changes. CLU is heterogeneously expressed in the hippocampus in non‐demented individuals and increased in AD. In the plasma, two CLU levels were measured: low in controls and MCI, and high in AD. To validate that the elevation in CLU is associated with conversion to AD, a replication study showed, in a second group MCI patients converting to AD in the follow‐up that CLU levels increased in 16/19 individuals. The increase in brain CLU occurs in AD models as in humans, and seems to precede plasma variations, which could make it an AD therapeutic target. Plasma CLU seems to be a promising marker of cognitive decline, and its association with AD may be a useful complementary diagnostic tool.

GABAergic signaling abnormalities in a novel CLU mutation Alzheimer's disease mouse model

Alzheimer's disease protective allele of Clusterin modulates neuronal excitability through lipid-droplet-mediated neuron-glia communication

Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology

Glutaminase C Regulates Microglial Activation and Pro-inflammatory Exosome Release: Relevance to the Pathogenesis of Alzheimer’s Disease

Immunity factor contributes to altered brain functional networks in individuals at risk for Alzheimer's disease: Neuroimaging-genetic evidence

Clusterin Is Required for β-Amyloid Toxicity in Human iPSC-Derived Neurons

Effect of CLU Genetic Variants on Cerebrospinal Fluid and Neuroimaging Markers in Healthy, Mild Cognitive Impairment and Alzheimer’s Disease Cohorts

Cholinergic Grb2-Associated-Binding Protein 1 Regulates Cognitive Function.

Astrocytic response mediated by the CLU risk allele inhibits OPC proliferation and myelination in a human iPSC model

Reduction in GABAB on glia induce Alzheimer's disease related changes

Altered Expression of Aβ Metabolism-Associated Molecules from D-Galactose/alcl3 Induced Mouse Brain

Genetically-mediated Grey and White Matter Alteration in Normal Elderly Individuals with the CLU-C Allele Gene

Chloride intracellular channel 4 blockade improves cognition in mice with Alzheimer's disease: CLIC4 protein expression and tau protein hyperphosphorylation

Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model

Alzheimer's disease risk variant in CLU is associated with neural inefficiency in healthy individuals

Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer’s Disease

Lack of Human-Like Extracellular Sortilin Neuropathology in Transgenic Alzheimer’s Disease Model Mice and Macaques

Intraventricular Infusion of Clusterin Ameliorated Cognition and Pathology in Tg6799 Model of Alzheimer’s Disease

Cognitive impairment in Alzheimer's disease FAD 4T mouse model: Synaptic loss facilitated by activated microglia via C1qA

Pathophysiologic abnormalities in transgenic mice carrying the Alzheimer disease PSEN1 Δ440 mutation

Brain and plasmatic CLUSTERIN are translational markers of Alzheimer's disease